Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not a subscriber? Subscribe now for unlimited access to online articles.

Susan Young Rojahn

A View from Susan Young Rojahn

FDA Approves First Pill to Reduce Chance of HIV Infection

A daily dose of Gilead’s Truvada reduces infection in high-risk, uninfected men.

  • July 16, 2012

Today, the U.S. Food and Drug Administration announced its approval of the first drug shown to reduce the chance of HIV infection in high-risk individuals: those who are uninfected and are sexually active with HIV-infected partners. The drug, called Truvada, is manufactured by San Francisco-area biotech Gilead Sciences and is taken as a daily oral pill. 

Left unchecked, HIV, the virus that causes AIDS, can destroy an infected person’s immune system and leave them vulnerable to life-threatening infections from other pathogens or cancer. Scientific progress in recent years has enabled HIV-infected patients to stave off the symptoms AIDS for years (see Technology Review’s Can AIDS be cured? from two years ago) but there is still no cure.

Truvada prevents HIV from reproducing inside human cells is already approved as a treatment for infected patients when combined with other anti-viral medications.

The prevention-capability of Truvada was tested in two clinical trials. In nearly 2,500 men with high-risk behavior, which included having unprotected sex with infected partners or with partners with unknown HIV-status, the anti-viral compound reduced the risk of an HIV infection by 42 percent if the drug was taken as directed. In another study with nearly 4,800 heterosexual couples in which one partner was infected and the other was not, Truvada reduced the risk of infection by 75 percent.

Gilead will collect viruses from any patient who acquires HIV while on Truvada in order to look for resistance to the compound.

Cut off? Read unlimited articles today.

Become an Insider
Already an Insider? Log in.
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to MIT Technology Review.
  • Print + All Access Digital {! insider.prices.print_digital !}* Best Value

    {! insider.display.menuOptionsLabel !}

    The best of MIT Technology Review in print and online, plus unlimited access to our online archive, an ad-free web experience, discounts to MIT Technology Review events, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    6 bi-monthly issues of print + digital magazine

    10% discount to MIT Technology Review events

    Access to entire PDF magazine archive dating back to 1899

    Ad-free website experience

    The Download: newsletter delivered daily

  • All Access Digital {! insider.prices.digital !}*

    {! insider.display.menuOptionsLabel !}

    The digital magazine, plus unlimited site access, our online archive, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    Digital magazine (6 bi-monthly issues)

    Access to entire PDF magazine archive dating back to 1899

    The Download: newsletter delivered daily

  • Print Subscription {! insider.prices.print_only !}*

    {! insider.display.menuOptionsLabel !}

    Six print issues per year plus The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Print magazine (6 bi-monthly issues)

    The Download: newsletter delivered daily

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.